

A Leap Forward: FDA’s Draft Guidance on Clinical Trials with Psychedelic Drugs
In a landmark move, the U.S. Food and Drug Administration (FDA) has issued its first draft guidance concerning clinical trials with psychedelic drugs. This monumental step marks a new era in the exploration of the therapeutic potentials of these substances. The guidance is aimed at advising researchers on the design and conduct of clinical studies involving psychedelic drugs.